



The Nifty previous session ended 0.95% up at 16013.45. It opened gap-down again and remained choppy, however, sharp recovery in the later half led to closing in green. Chart pattern suggesting intraday pullback towards critical resistances may again find sellers as the broader downtrend is still intact. Hence, staying cautious on rise is advised. Immediate thick resistance zone is placed in the price range of 16100-16150. The Nifty short-term trading range likely to be 15950-16150.

On the Nifty hourly chart, direction of the RSI suggesting intraday pullback may progress further towards 16150 levels, however, we still prefer sell on rise as the broader downtrend is still intact. Staying cautious on rise is advised.

Nifty patterns on multiple periods suggest; the Benchmark Index ended with a bullish candle, however, it is still trading below the thick resistance placed around 16150 levels. Failing to breakout 16150 may again push the Benchmark Index back towards 15800 levels.

Nifty Crucial Supports & Resistances-

Supports- 15950, 15800 Resistances- 16100, 16150

Open Positional Calls-

T+14 INST POSITIONAL BUY-

| Cash Segment | TECH MAHINDRA @ 1430-1420, TGT- 1520, Closing SL- below 1370

T+3 Buy-

| Cash Segment | HCL TECH @ 1165-1160, TGT- 1190, SL- below 1145

T+3 Buy-

| Cash Segment | INFY @ 1765-1760, TGT- 1820, SL- below 1730

T+14 INST POSITIONAL BUY-

| Cash Segment | WIPRO @ 585-580, TGT- 630, Closing SL- below 555

BTST

| Cash Segment | LT @ 1662-1660, TGT- 1700, Closing SL- below 1640

BTST-

| Cash Segment | BHEL @ 49.50-49, TGT- 53, SL- below 47

Key Contents	Page No.
Domestic News	4

Nifty Intraday Chart



Market in Retrospect

India's stock benchmarks snapped a four-day losing streak, aided by gains in information technology, healthcare and realty stocks, as markets rebounded in the second half of Tuesday's session.

Nifty index ended 0.95% higher at 16,013. The broader markets represented by the Nifty 500 Index ended 1.05% higher, ending at 13,707. Among the sectorial indices, Nifty Realty was the top gainer, gaining by 3.25%, followed by Nifty IT which was gaining by 2.69%. Nifty Metal was the top loser, losing by 1.48%

IOCL was the top gainer, gaining by 4.28%, followed by Sun Pharma and Tata Consumer Products which was gaining by 3.93% & 3.61% respectively. Hindalco Industries was the top loser, losing by 4.81%, followed by ONGC and Tata Steel which fell by 4.20% & 1.73% respectively.

The Advance : Decline ratio stood at 1503:619.

Market Turnover (In Crore) 08-03-2022

Name	Last	Previous
NSE Cash	NA	71007.03
NSE F&O	NA	5294405.85
BSE Cash	5,170.93	7,001.72
BSE F&O	*NA	76.07

FII Derivatives Flow (In Crore) 07-03-2022*

Instrument	Purchase	Sale	Net
Index Future	8060.09	9822.24	1762.15
Index Option	291021.81	288224.71	2797.1
Stock Future	17640.95	18361.06	720.11
Stock Option	14571.35	14693.80	122.45

Institutional Flow (In Crore) 08-03-2022

Institution	Purchase	Sale	Net
FII	8283.13	16425.73	8142.60
DII	12923.51	6433.92	6489.59

*Data not updated till 7:40PM

NIFTY Top Gainers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
IOCL	4.28	1.78	22322573	16781610
Sun Pharmaceutical	3.93	1.32	4864275	3547172
Tata Con Products	3.61	4.86	2850859	2191320
TCS	3.30	1.29	3300992	2680542
Cipla	3.02	4.81	5826939	2498152

NIFTY Top Losers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
JSW Steel	1.15	0.38	5422987	7018179
Britannia Industries	1.26	9.15	541966	463363
Tata Steel	1.73	3.99	9107822	17445250
ONGC	4.20	11.48	73127816	53771210
Hindalco Industries	4.81	2.82	19477245	27318290

Bulk and Block Deals

<https://www.nseindia.com/products/content/equities/equities/bulk.htm>
<http://www.bseindia.com/markets/equity/EQReports/BulknBlockDeals.aspx>

Sensex Intraday Chart



Market in Detailed (Updated after 4:00 PM)

Indian Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Sensex	53424.09	581.34	1.10	5.02	7.58	8.91	5.91
Nifty	16013.45	150.30	0.95	4.65	7.26	8.34	7.07
BSE M Cap	22431.02	322.08	1.46	3.96	7.81	12.07	8.63
BSE S Cap	26021.90	340.78	1.33	2.40	10.48	9.60	23.52
Nifty MC 100	27198.55	332.65	1.24	3.63	9.09	11.60	12.63
BSE Auto	21801.70	132.32	0.61	11.43	15.52	12.52	8.04
BSE Capgoods	26022.24	312.64	1.22	5.91	9.43	6.63	16.82
BSE FMCG	12531.58	129.12	1.04	3.66	7.60	9.15	2.18
BSE Metal	21432.38	423.59	1.94	3.12	4.37	9.39	52.45
BSE Oil&Gas	17686.27	175.25	0.98	2.14	2.99	1.81	8.17
BSE Healthcare	23126.43	442.89	1.95	0.98	4.92	7.70	8.73
BSE Power	3842.38	28.41	0.74	0.31	0.70	7.98	51.82
BSE Realty	3226.58	99.88	3.19	6.91	12.39	18.77	14.41
BSE ConsDur	40130.56	15.94	0.04	6.89	5.37	7.87	22.62
BSE Bank	38051.11	324.25	0.86	8.61	12.79	10.22	4.19
BSE IT	34496.57	821.75	2.44	2.97	0.23	2.18	34.39

Bond Markets

Name	Yield	Net Chng	%1D	%5D	%1M	%3M	%1Y
US	1.84	0.07	3.87	6.63	6.17	21.10	15.80
UK	1.37	0.07	5.37	21.81	7.72	77.29	82.23
Brazil	5.12	0.08	1.61	2.38	4.19	11.79	23.07
Japan	0.16	0.01	8.84	9.09	26.61	220.00	30.08
Australia	2.23	0.10	4.45	1.97	5.24	37.72	25.97
India	6.90	0.01	0.10	1.01	1.26	8.63	10.89
Switzerland	0.23	0.04	24.18	172.29	36.52	185.28	192.62
Germany	0.08	0.09	626.67	209.72	70.19	125.24	128.52

Currency

Name	Rate	Net Chng	%1D	%5D	%1M	%3M	%1Y
INR	76.91	0.05	0.07	2.04	2.81	1.90	4.76
USD Index	99.08	0.22	0.22	1.71	3.59	3.32	7.33
YUAN	6.32	0.00	0.05	0.09	0.78	0.42	3.30
GBP	1.31	0.00	0.02	1.67	3.26	0.77	5.22
EUR	1.09	0.00	0.29	2.15	4.63	4.03	8.11
YEN	115.66	0.34	0.29	0.64	0.10	1.72	5.85

Freight

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Baltic Dry	2235.00	87.00	4.05	9.56	48.70	34.71	20.62
Baltic Dirty	1517.00	43.00	2.92	4.69	122.76	96.76	125.74
SG Dubai HY	6.56	0.81	14.09	19.93	16.75	70.39	400.76

Global Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Dow Jones	32817.38	797.42	2.37	3.17	7.46	8.22	3.19
Nasdaq	12830.96	482.48	3.62	6.69	9.61	18.72	1.76
S&P 500	4201.09	127.78	2.95	3.95	7.09	10.64	9.94
FTSE100	6953.95	8.38	0.12	5.17	8.14	5.26	3.45
CAC40	6049.62	60.04	1.00	5.54	14.03	13.86	2.36
DAX	12914.65	66.99	0.52	7.21	15.36	17.76	10.29
Mexico IPC	52312.61	1009.44	1.89	2.04	0.03	2.46	11.13
Brazil Bovespa	111593.5	2880.30	2.52	0.00	0.57	3.24	0.89
Russian RTS	936.94	194.03	26.12	26.12	35.17	43.12	35.27
Japan Nikkei	24790.95	430.46	1.71	7.65	9.14	14.10	13.75
Hang Seng	20765.87	291.76	1.39	8.77	14.65	13.46	27.24
Taiwan Index	16825.25	353.44	2.06	6.00	6.35	5.65	6.35
Shanghai Comp	3293.53	79.33	2.35	5.60	4.61	9.46	3.74
KOSPI	2622.40	28.91	1.09	2.84	4.52	12.64	12.47
Malaysia KLCI	1546.87	25.69	1.63	3.11	1.10	3.54	4.03
Jakarta Comp	6814.18	54.88	0.80	1.07	0.36	3.19	9.05
Philippine SE	6977.73	310.34	4.26	5.77	6.44	2.37	3.27
Thai Exch	1619.10	7.60	0.47	4.44	3.87	0.05	4.88

Indian Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
NYMEX Crude	122.55	3.21	2.69	18.57	37.21	69.44	88.49
BRENT Crude	126.89	3.70	3.00	20.90	41.99	69.35	105.06
Natural Gas	4.65	0.19	3.95	1.51	10.05	29.85	86.05

LME

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Gold(\$/Ounce)	2008.29	10.85	0.54	3.27	10.03	12.67	19.33
Silver(\$/Ounce)	26.19	0.55	2.13	3.27	13.04	16.82	4.30
Aluminium	3732.00	145.50	3.75	10.15	17.65	41.54	71.37
Copper	10255.50	446.50	4.17	3.39	4.58	6.69	15.06
Zinc	4133.00	61.75	1.52	12.07	14.00	25.69	50.09
Lead	2446.25	8.50	0.35	2.42	11.22	11.42	23.33

Agro Commodities

Name	Price	Net Chng	%1D	%5D	%1M	%3M	%1Y
Coffee	224.20	0.05	0.02	5.00	10.10	7.98	63.29
Cotton	117.10	0.16	0.14	4.60	5.59	11.18	39.70
Sugar	19.11	0.16	0.83	4.20	7.84	1.55	27.40
Wheat	1322.00	28.00	2.16	34.35	68.62	65.41	103.23
Soybean	1686.25	26.75	1.61	0.22	7.23	32.15	38.33

Alembic Pharmaceuticals joint venture gets USFDA nod for anti-fungal drug

Alembic Pharmaceuticals Ltd joint venture, Aleor Dermaceuticals Ltd (Aleor), has received final approval from the US health regulator for its generic version of Nystatin and Triamcinolone Acetonide ointment used for the treatment of cutaneous candidiasis. Cutaneous candidiasis is an infection of the skin and nails caused by the candida fungus. The approval by the US Food & Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) for Nystatin and Triamcinolone Acetonide Ointment of strength 100,000 units/gram. The approved ANDA is therapeutically equivalent to the reference-listed drug product (RLD) Nystatin and Triamcinolone Acetonide ointment of Taro Pharmaceuticals USA Inc. The company further said Nystatin and Triamcinolone Acetonide ointment is indicated for the treatment of cutaneous candidiasis. It has been demonstrated that the nystatin-steroid combination provides greater benefit than the nystatin component alone during the first few days of treatment.

Oil companies to determine fuel prices: Hardeep Singh Puri

Amid the Russia-Ukraine war, Union Minister for Petroleum and Natural Gas Hardeep Singh Puri on Tuesday said oil companies will determine the fuel prices, even as he said there will be no shortage of crude oil in the country. Crude oil prices rose by Rs 37 to Rs 9,321 per barrel on Tuesday as participants widened their positions on a firm spot demand. On the Multi Commodity Exchange, crude oil for March delivery traded higher by Rs 37 or 0.4 per cent at Rs 9,321 per barrel in 9,660 lots.

Adani-IOCL sign agreement for augmenting crude volumes

Adani Ports and Special Economic Zone Ltd (APSEZ) has signed an agreement with Indian Oil Corp Ltd (IOCL) towards augmentation of IOC's crude oil volumes at the Mundra port. The state-run refiner shall expand its existing crude oil tank farm at APSEZ's Mundra Port, thus enabling it to handle and blend an additional 10 million metric tons crude oil per annum at Mundra. This will support IOCL's expansion of its Panipat Refinery (Haryana). IOCL is raising the capacity at its Panipat Refinery by 66% to 25 MMPTA. IOCL, which accounts for nearly half of India's petroleum products, has a refining capacity of 80.55 MMTPA and over 15,000 kilometer of pipeline network. Part of IOCL's current crude oil requirement of 15 MMTPA for its Panipat Refinery is handled at Mundra Port. The Mundra SBM is located 3-4 kms off the coast where Very Large Crude Carriers (VLCCs) unload crude oil. An undersea pipeline then transports this crude oil to the crude oil tank farm and thereafter to the refinery at Panipat via the Mundra Panipat Pipeline (MPPL). IOCL is currently operating a crude oil tank farm in an exclusive area in Adani's Mundra Special Economic Zone, consisting of 12 tanks with a total capacity of 720,000 kilo liters.

India expects private coal mines to produce at least 350 mln tonnes by 2030

India expects coal mines owned by private companies to produce 350-400 million tonnes of coal by 2030, a senior coal ministry official told an industry conference on Tuesday, potentially reducing the country's dependence on imports. India, the world's second largest coal consumer behind China, opened up coal mining to the private sector companies, such as Adani Enterprises and Vedanta, for the first time in 2020, after years of lobbying by coal users to privatise coal mining. The increased domestic production could mean lower imports. Indonesia, Australia and South Africa are the country's largest suppliers, and together account for over 90% of coal imports. India's imports have fallen in the recent months due to high global prices, increasing dependence on Coal India. The state-run miner accounts for over 80% of India's domestic output, and is targeting an output of 670 million tonnes in 2021-22.

JSW Steel output jumps 21 pc to 1.58 MT in February

JSW Steel on Tuesday registered a 21 per cent year-on-year (y-o-y) jump in its crude steel production to 1.58 million tonnes (MT) for February. In a statement, the JSW Group company said its output had stood at 1.31 MT in February 2021. JSW Steel's production of flat-rolled products rose 25 per cent to 1.15 MT in February 2022, compared with 0.93 MT in the year-ago period. Its output of long-rolled products stood at 0.37 MT, an eight per cent rise compared with 0.34 MT a year ago. JSW Steel is the flagship business of the USD 13-billion diversified JSW Group, which has a presence in sectors such as energy, infrastructure, cement, paints, sports and venture capital.

India expects private coal mines to produce at least 350 mln tonnes by 2030

India expects coal mines owned by private companies to produce 350-400 million tonnes of coal by 2030, a senior coal ministry official told an industry conference on Tuesday, potentially reducing the country's dependence on imports. India, the world's second largest coal consumer behind China, opened up coal mining to the private sector companies, such as Adani Enterprises and Vedanta, for the first time in 2020, after years of lobbying by coal users to privatise coal mining. The increased domestic production could mean lower imports. Indonesia, Australia and South Africa are the country's largest suppliers, and together account for over 90% of coal imports. India's imports have fallen in the recent months due to high global prices, increasing dependence on Coal India. The state-run miner accounts for over 80% of India's domestic output, and is targeting an output of 670 million tonnes in 2021-22.

Goodluck India exports Rs 1,000-cr goods during ongoing fiscal

Goodluck India exported goods worth Rs 1,000 crore during the ongoing financial year, mainly to its customers in Europe and North America, registering a 100 per cent. The New Delhi-based company had made exports valuing Rs 475 crore in the entire 2020-21 financial year.

Alembic Pharmaceuticals' JV gets USFDA final nod for anti-fungal drug

Alembic Pharmaceuticals Ltd on its joint venture, Aleor Dermaceuticals Ltd (Aleor), has received final approval from the US health regulator for its generic version of Nystatin and Triamcinolone Acetonide ointment used for the treatment of cutaneous candidiasis. Cutaneous candidiasis is an infection of the skin and nails caused by the candida fungus. The approval by the US Food & Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) for Nystatin and Triamcinolone Acetonide Ointment of strength 100,000 units/gram. The approved ANDA is therapeutically equivalent to the reference-listed drug product (RLD) Nystatin and Triamcinolone Acetonide ointment of Taro Pharmaceuticals USA Inc.

Analyst Certification:

We /I, Jaydeb Dey and Shreyansh N. Mehta Research Analyst(S) of SMIFS Limited (in short “SMIFS / the Company”), authors and the names subscribed to this Research Report, hereby certify that all of the views expressed in this Research Report accurately reflect our views about the subject issuer(s) or securities and distributed as per SEBI (Research Analysts) Regulations 2014. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this Research Report. It is also confirmed that We/I, the above mentioned Research Analyst(s) of this Research Report have not received any compensation from the subject companies mentioned in the Research Report in the preceding twelve months and do not serve as an officer, director or employee of the subject companies mentioned in the Research Report.

Terms & Conditions and Other Disclosures:

SMIFS Limited is engaged in the business of Stock Broking, Depository Services, Portfolio Management and Distribution of Financial Products. SMIFS Limited is registered as Research Analyst Entity with Securities & Exchange Board of India (SEBI) with Registration Number – INH300001474.

SMIFS and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Research Analysts. SMIFS generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

The information and opinions in this Research Report have been prepared by SMIFS and are subject to change without any notice. The Research Report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of SMIFS Limited. While we would endeavor to update the information herein on a reasonable basis, SMIFS is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent SMIFS from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or policies of SMIFS, in circumstances where SMIFS might be acting in an advisory capacity to this company, or in certain other circumstances.

This Research Report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This Research Report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Securities as defined in clause (h) of section 2 of the Securities Contract Act, 1956, includes Financial Instruments, Currency and Commodity Derivatives. Though disseminated to all the customers simultaneously, not all customers may receive this Research Report at the same time. SMIFS will not treat recipients as customers by virtue of their receiving this Research Report. Nothing in this Research Report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this Research Report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. SMIFS accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this Research Report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document

to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. The information given in this report is as of date of this report and there can be no assurance that future results or events will be consistent with this information. The information provided in this report remains, unless otherwise stated, the copyright of SMIFS. All layout, design, original artwork, concepts and intellectual Properties remains the property and copyright of SMIFS and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the SMIFS.

SMIFS shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, breakdown of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of SMIFS to present the data. In no event shall SMIFS be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the SMIFS through this report.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (a) Exchange Rates can be volatile and are subject to large fluctuations; (b) the value of currencies may be affected by numerous market factors, including world and notional economic, political and regulatory events, events in Equity & Debt Markets and changes in interest rates; and (c) Currencies may be subject to devaluation or government imposed Exchange Controls which could affect the value of the Currency. Investors in securities such as Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Since associates of SMIFS are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this Research Report.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may: (i) from time to time may have long or short positions in, and buy or sell the Securities, mentioned herein or (ii) be engaged in any other transaction involving such Securities and earn brokerage or other compensation of the Subject Company/ companies mentioned herein or act as an Advisor or Lender/Borrower to such Companies or have other potential/material Conflict of Interest with respect to any recommendation and related information and opinions at the time of the publication of the Research Report or at the time of Public Appearance.

SMIFS does not have proprietary trades but may at a future date, opt for the same with prior intimation to Clients/ Investors and extant Authorities where it may have proprietary long/short position in the above Scrip(s) and therefore should be considered as interested.

The views provided herein are general in nature and do not consider Risk Appetite or Investment Objective of any particular Investor; Clients/ Readers/ Subscribers of this Research Report are requested to take independent professional advice before investing, however the same shall have no bearing whatsoever on the specific recommendations made by the analysts, as the recommendations made by the analysts are completely independent views of the Associates of SMIFS even though there might exist an inherent conflict of interest in some of the stocks mentioned in the Research Report.

The information provided herein should not be construed as invitation or solicitation to do business with SMIFS.

SMIFS or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the Research Report as of the last day of the month preceding the publication of the Research Report.

SMIFS encourages independence in Research Report preparation and strives to minimize conflict in preparation of Research Report. Accordingly, neither SMIFS and their Associates nor the Research Analysts and their relatives have any material conflict of interest at the time of publication of this Research Report or at the time of the Public Appearance, if any.

SMIFS or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

SMIFS or its associates might have received any compensation from the companies mentioned in the Research Report during the period preceding twelve months from the date of this Research Report for services in respect of managing or co-managing public offerings, corporate finance, investment banking, brokerage services or other advisory service in a merger or specific transaction from the subject company.

SMIFS or its associates might have received any compensation for products or services other than investment banking or brokerage services from the subject companies mentioned in the Research Report in the past twelve months.

SMIFS or its associates or its Research Analysts did not receive any compensation or other benefits whatsoever from the subject companies mentioned in the Research Report or third party in connection with preparation of the Research Report.

Compensation of Research Analysts is not based on any specific Investment Banking or Brokerage Service Transactions.

The Research Analysts might have served as an officer, director or employee of the subject company.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may have been engaged in market making activity for the companies mentioned in the Research Report.

SMIFS may have issued other Research Reports that are inconsistent with and reach different conclusion from the information presented in this Research Report.

A graph of daily closing prices of the securities/commodities is also available at www.nseindia.com and/or www.bseindia.com, www.mcxindia.com and/or www.icex.com.

SMIFS submit' s that no material disciplinary action has been taken on the Company by any Regulatory Authority impacting Equity Research Analysis activities in last 3 years.

This Research Report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SMIFS and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

Specific Disclosures

- SMIFS, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- SMIFS, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company.
- SMIFS, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months.
- SMIFS, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as director/officer/employee in the subject company
- SMIFS has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- SMIFS has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- SMIFS has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months.
- SMIFS has not received any compensation or other benefits from third party in connection with the research report.
- SMIFS has not engaged in market making activity for the subject company

Analyst holding in stock: **NO**

Key to SMIFS Investment Rankings

Buy: Return >15%, Accumulate: Return between 5% to 15%, Reduce: Return between -5% to +5%, Sell: Return < -5%

Contact us:

SMIFS Limited. (<https://www.smifs.com/>)

Compliance Officer:

Sudipto Datta,

Vaibhav, 4 Lee Road, Kolkata 700020, West Bengal, India.

Contact No.: +91 33 4011 5401 /91 33 6634 5401

Email Id.: compliance@smifs.com
